The relative contribution of CHK1 and CHK2 to Adriamycin-induced checkpoint.
Exp Cell Res
; 304(1): 1-15, 2005 Mar 10.
Article
em En
| MEDLINE
| ID: mdl-15707569
ABSTRACT
Topoisomerase II poisons like Adriamycin (ADR, doxorubicin) are clinically important chemotherapeutic agents. Adriamycin-induced DNA damage checkpoint activates ATM and ATR, which could in turn inhibit the cell cycle engine through either CHK1 or CHK2. In this study, we characterized whether CHK1 or CHK2 is required for Adriamycin-induced checkpoint. We found that both CHK1 and CHK2 were phosphorylated after Adriamycin treatment. Several lines of evidence from dominant-negative mutants, short hairpin RNA (shRNA), and knockout cells indicated that CHK1, but not CHK2, is critical for Adriamycin-induced cell cycle arrest. Disruption of CHK1 function bypassed the checkpoint, as manifested by the increase in CDC25A, activation of CDC2, increase in histone H3 phosphorylation, and reduction in cell survival after Adriamycin treatment. In contrast, CHK2 is dispensable for Adriamycin-induced responses. Finally, we found that CHK1 was upregulated in primary hepatocellular carcinoma (HCC), albeit as an inactive form. The presence of a stockpile of dormant CHK1 in cancer cells may have important implications for treatments like topoisomerase II poisons. Collectively, the available data underscore the pivotal role of CHK1 in checkpoint responses to a variety of stresses.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Proteínas Quinases
/
Doxorrubicina
/
Proteínas Serina-Treonina Quinases
/
Proteínas de Ciclo Celular
Idioma:
En
Ano de publicação:
2005
Tipo de documento:
Article